GlassScriptPhysician profile
Jonathan Allen Miller
NPI 1346637048
$4,216.97
in general payments reported to CMS, 2019-2025
26 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what 78% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $34.74 · 2021: $373 · 2022: $592 · 2023: $1,036 · 2024: $986 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,216.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $675.87 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $625.24 | 2020-2025 | |
| Abbvie INC. | $579.38 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $523.61 | 2023-2025 | Ilumya |
| Genzyme Corporation | $230.25 | 2021-2025 | |
| Janssen Biotech, INC. | $221.89 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Sientra, INC. | $147.48 | 2021 | |
| Galderma Laboratories, L.P. | $135.85 | 2025 | Nemluvio |
| Ucb, INC. | $130.86 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $129.30 | 2023-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $114.04 | 2021-2024 | |
| Leo Pharma INC. | $101.39 | 2024-2025 | Adbry |
| Almirall LLC | $69.64 | 2022-2025 | Seysara |
| Pfizer INC. | $65.75 | 2023-2024 | |
| Incyte Corporation | $64.61 | 2021-2023 | Opzelura |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $61.53 | 2022-2024 | Libtayo |
| Dermavant Sciences, INC. | $60.62 | 2023 | Vtama |
| Organon LLC | $53.53 | 2025 | Vtama |
| Amgen INC. | $49.88 | 2020-2023 | Otezla |
| Verrica Pharmaceuticals INC. | $41.09 | 2024 | Ycanth |
| Bioventus LLC | $34.36 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.75 | 2024 | |
| Biofrontera INC. | $24.83 | 2024 | Rhodoled Xl, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $20.70 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $13.60 | 2024 | Xtrac |
| Smith+Nephew, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.